Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 10Thoracic 6Head & Neck 5Lymphoid 3Sarcoma 2Endocrine 2Breast 2Other solid neoplasm 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Neoplasms by Histologic Type 1Lymphoma 1

Interventions

Cyclophosphamide 886Rituximab 864Vincristine 382Etoposide 381fludarabine 342Cytarabine 341Doxorubicin 340fludarabine phosphate 319Methotrexate 310Dexamethasone 283Prednisone 282Lenalidomide 245Filgrastim 228Melphalan 200Peripheral Blood Stem Cell Transplantation 184Radiotherapy 175Whole-Body Irradiation 172Busulfan 165Mycophenolic Acid 161venetoclax 158Bendamustine Hydrochloride 158Granulocyte Colony-Stimulating Factor 151Tacrolimus 145ibrutinib 144Bortezomib 138obinutuzumab 125Gemcitabine 113Cyclosporine 110Antilymphocyte Serum 103Carmustine 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × penpulimab × Lymphoid × Clear all
NCT06516978 2024-07-24

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
528 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05680038 2023-01-11

Penpulimab in Maintenance Therapy in Lymphoma

The First Affiliated Hospital with Nanjing Medical University

Unknown
167 enrolled
Lymphoid

Lymphoma

NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
54 enrolled
Lymphoid

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡